Knome taps Pfizer vet as new CEO

With plans to up its game in the biopharma and healthcare arenas, genome interpretation provider Knome has hired veteran biotech executive Martin Tolar as its new chief executive, the company announced today. Prior CEO Jorge Conde has been named chief strategy officer and reports to the new chief executive, Tolar said in an interview with FierceBiotech IT. Story

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.